to attend The 2011 World Stem Cell Summit in Pasadena, California October 3-5

Top Quote is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements in the regenerative medicine sector. End Quote
  • (1888PressRelease) September 09, 2011 - Jason Gruner, Founder of Stem Cell Media, LLC and Sai Rosen, Director of Client Services and will be in attendance for the 2011 World Stem Cell Summit taking place October 3-5 at the Pasadena Convention Center in Pasadena, CA. The event is produced by the Genetics Policy Institute (GPI).

    The annual World Stem Cell Summit is the global stem cell and regenerative medicine community's flagship event. The Genetics Policy Institute (GPI), is a 501c3 not-for-profit organization that leads in the production of the event. The 2011 Organizing Partners include the City of Hope, Cedars Sinai Regenerative Medicine Institute, Caltech, California Institute for Regenerative Medicine (CIRM), Keck School of Medicine of USC, Children's Hospital Los Angeles and the Consulate General of Canada in Los Angeles, and other leading research institutions. The 2011 World Stem Cell Summit will draw 1500+ attendees from 30 countries, research institutions, industry leaders, ethics, policy, law, finance, insurance and many patient advocacy organizations. Over 250 institutions, state biotech associations, foundations and other not-for-profit organizations, media partners endorse the Summit. To learn more about the World Stem Cell Summit visit at

    Sai Rosen commented, "We are pleased to have been invited to the World Stem Cell Summit in Pasadena. The Genetic Policy Institute once again has masterfully brought together regenerative medicine stakeholders from around the world."

    Bernard Siegel, Executive Director & Founder of the Genetics Policy Institute reflected, "Persons with a stake in stem cell companies, whether they are patients or investors, have reason to attend the World Stem Cell Summit. We have the top executives and researchers throughout industry attending including the CEO's from Biotime, Advanced Cell Technology, StemCells, Inc., Athersys, Celgene, Organova, Neuralstem, Pluristem, Stem Cell Technologies, Akron Biotech, Coronado Biosciences, Medipost, Cell Line Genetics, Cellerant and more. It's the whole stem cell universe gathered at one place at one time."

    Jason Gruner went on to say, "If you are a stakeholder in regenerative medicine, it is of paramount importance to attend the Summit. Validation of stem cell technology to treat unmet medical needs is expediting the necessity for stakeholders to join together in a cohesive voice."

    Register today at If you are a Patient, Caregiver to patients, and Student please contact Alan Fernandez, Director Pubic Outreach & Development of the Genetics Policy Institute, to register at 650-847-1640 or via email alan ( @ ) genpol dot org dot

    To find out more about the publicly traded regenerative medicine companies please visit is currently following the below companies.

    Advanced Cell Technology (OTC:ACTC), Geron Corp. (NASDAQ:GERN), BioTime Inc. (AMEX:BTX),Aastrom Biosciences Inc. (NASDAQ:ASTM), Athersys Inc. (NASDAQ:ATHX), International Stem Cell Corp. (OTC:ISCO), MultiCell Technologies, Inc. (OTC:MCET), StemCells, Inc. (NASDAQ:STEM), ThermoGenesis Corp. (NASDAQ:KOOL), Neostem Inc. (AMEX:NBS), RTI Biologics Inc. (NASDAQ:RTIX), Pluristem Therapeutics Inc. (NASDAQ:PSTI) Bio-Matrix Scientific Group, Inc. (PINK:BMSN), Neostem Inc. (AMEX:NBS) Opexa Therapeutics Inc. (NASDAQ:OPXA), STEM CELL AUTHORITY Ltd. (PINK:SCAL), Brainstorm Cell Therapeutics Inc. (OTC:BCLI), Stem Cell Therapeutics Corp. (CVE:SSS), CRYO-CELL International, Inc. (OTC:CCEL), CellCyte Genetics Corporation (OTC:CCYG), Stem Cell Innovations Inc. (PINK:SCLL). BioMimetic Therapeutics, Inc. (NASDAQ:BMTI), Mesoblast Ltd. (ASX:MSB), Cytori Therapeutics Inc. (NASDAQ:CYTX), SANUWAVE Health, Inc. (OTC:SNWV), Stem Cell Assurance, Inc. (Pink:SCLZ), Proteonomix, Inc. (OTC:PROT), Vitro Diagnostics, Inc. (PINK:VODG), Genesis Biopharma Inc. (OTC:GNBP), Medistem Inc. (PINK:MEDS), Bioheart, Inc. (OTC:BHRT), XYTOS Inc. (PINK:XYTS), ReNeuron Group Plc. (LON:RENE), BioLife Solutions, Inc. (OTC:BLFS), Life Technologies Corp. (NASDAQ:LIFE), China Cord Blood Corp. (NYSE:CO), Talon Therapeutics Inc. (OTC:TLON), RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) Regenicin, Inc. (OTC:RGIN), RegenoCELL Therapeutics Inc. (OTC:RCLL), American CryoStem Corp. (OTC:CRYO), BIOSTEM US Corp. (PINK:BOSM), Fibrocell Science, Inc. (OTC:FCSC), Shrink Nanotechnologies, Inc. (PINK:INKN), Nuvilex Inc. (PINK:NVLX), Providential Holdings, Inc. (PINK:PHIE), Osiris Therapeutics, Inc. (NASDAQ:OSIR), InoLife Technologies Inc. (PINK:INOL), Intellicell Biosciences Inc. (PINK:SVFC), Invivo Therapeutics Holdings Corp. (OTC:NVIV), AmStem Corp. (PINK:AMST), ImmuneRegen BioSciences, Inc. (PINK:IRBS), RBC Life Sciences (PINK:RBCL), ProtoKinetix (OTC:PKTX), Tengion (NASDAQ:TNGN) and Pathfinder Cell Therapy, Inc. (PINK:SYMD).

    Disclosure: Stem Cell Media, LLC., nor any of its companies was compensated for this release. Always consult an investment professional before an investment.

  • FB Icon Twitter Icon In-Icon
Contact Information